Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Glucotrack, Inc.GCTK · Entity 8422 | Director | March 25, 2025 | October 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Glucotrack, Inc.
Report date March 25, 2025 · Filed October 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 4,692 |
Ending reported balance
After 2025-10-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-03-25 · Grant · Acquired 75 · Balance 75 Row 2 · 2025-07-11 · Grant · Acquired 3,332 · Balance 3,407 Row 3 · 2025-10-03 · Grant · Acquired 1,285 · Balance 4,692 |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.40 · Expires 2035-10-03 | Direct | 4,055 |
Reported balance
After 2025-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-10-03 · Grant · Acquired 4,055 · Balance 4,055 F1: Each option grant has a vesting commencement date of July 1 of the applicable calendar year and vests in 12 equal monthly installments over the 12-month period ending June 30 of the following year, subject to the reporting person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each option grant has a vesting commencement date of July 1 of the applicable calendar year and vests in 12 equal monthly installments over the 12-month period ending June 30 of the following year, subject to the reporting person's continued service to the Issuer through each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
DEXCOM INC
Report date March 10, 2023 · Filed March 14, 2023
Section 16 reporting ended · disclosed 2023-03-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,908 |
Last balance in matching sequence
After 2023-03-10 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2023-03-10 · Disposition to issuer · Disposed 3,275 · Balance 59,303 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Row 2 · 2023-03-10 · Disposition to issuer · Disposed 2,405 · Balance 56,898 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Row 3 · 2023-03-10 · Disposition to issuer · Disposed 5,990 · Balance 50,908 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 30,212 |
Reported balance
Holding disclosure · report date 2023-03-10 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 30,212 F3: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.
F3: Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2018 Filed Mar 15, 2018 01:02 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 2,221 | $60.73 | $134,882.66 |
DisclosureSEC source: 0001093557-18-000056 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,031 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 70,343 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 19,174 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 01:02 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 2,834 | $60.73 | $172,110.52 |
DisclosureSEC source: 0001093557-18-000056 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,252 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 70,343 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 19,174 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| March 08, 2018 Filed Mar 13, 2018 01:32 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 38,502 | $0.00 | $38.50 |
DisclosureSEC source: 0001093557-18-000036 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,086 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 70,343 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 19,174 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 22:06 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,245 | $61.23 | $198,691.35 |
DisclosureSEC source: 0001093557-17-000240 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,547 F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 55,678 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,917 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| November 29, 2017 Filed Dec 1, 2017 01:56 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6,490 | $60.00 | $389,400.00 |
DisclosureSEC source: 0001093557-17-000236 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,792 F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 55,678 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,917 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:23 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,347 | $71.81 | $240,359.45 |
DisclosureSEC source: 0001093557-17-000190 · edgardoc.xml · nonDerivative · entry 3 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,282 F4 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F3 · balance_after: Included in this number are 55,678 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,917 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:23 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 4,184 | $71.81 | $300,467.27 |
DisclosureSEC source: 0001093557-17-000190 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,629 F4 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F3 · balance_after: Included in this number are 55,678 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,917 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:23 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,244 | $72.27 | $234,441.28 |
DisclosureSEC source: 0001093557-17-000190 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,813 F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.81 to $72.52. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 55,678 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,917 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 21:54 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,244 | $71.18 | $230,921.22 |
DisclosureSEC source: 0001093557-17-000173 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,989 F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.00 to $71.37. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 21:32 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,200 | $71.55 | $228,972.48 |
DisclosureSEC source: 0001093557-17-000160 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,233 F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.00 to $72.20. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 21:27 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,200 | $69.06 | $220,988.80 |
DisclosureSEC source: 0001093557-17-000153 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,433 F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $68.50 to $69.60. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| May 10, 2017 Filed May 12, 2017 22:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,200 | $71.93 | $230,176.00 |
DisclosureSEC source: 0001093557-17-000121 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,633 F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 21:31 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,200 | $78.19 | $250,208.00 |
DisclosureSEC source: 0001093557-17-000099 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,833 F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 23:57 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,208 | $77.55 | $248,782.32 |
DisclosureSEC source: 0001093557-17-000073 · edgardoc.xml · nonDerivative · entry 4 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,033 F3 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 23:57 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 6,694 | $77.55 | $519,123.72 |
DisclosureSEC source: 0001093557-17-000073 · edgardoc.xml · nonDerivative · entry 3 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,241 F3 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 23:57 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,528 | $77.55 | $273,598.52 |
DisclosureSEC source: 0001093557-17-000073 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,935 F3 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 23:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,200 | $77.71 | $248,672.00 |
DisclosureSEC source: 0001093557-17-000073 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,463 F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| March 08, 2017 Filed Mar 11, 2017 01:47 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 28,761 | $0.00 | $28.76 |
DisclosureSEC source: 0001093557-17-000062 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,663 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| February 10, 2017 Filed Feb 15, 2017 00:49 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 727 | $79.30 Strike: $9.80 | $57,651.10 |
DisclosureSEC source: 0001093557-17-000031 · edgardoc.xml · derivative · entry 4 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 727 shares Expires 2020-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2017 Filed Feb 15, 2017 00:49 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,473 | $79.30 | $196,108.90 |
DisclosureSEC source: 0001093557-17-000031 · edgardoc.xml · nonDerivative · entry 3 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,872 F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 70,084 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 23,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 8,334 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| February 10, 2017 Filed Feb 15, 2017 00:49 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 727 | $79.30 | $57,651.10 |
DisclosureSEC source: 0001093557-17-000031 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,345 F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 70,084 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 23,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 8,334 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| February 10, 2017 Filed Feb 15, 2017 00:49 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 727 | $9.80 | $7,124.60 |
DisclosureSEC source: 0001093557-17-000031 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2017 Filed Jan 13, 2017 00:21 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 3,200 | $62.86 Strike: $9.80 | $201,152.00 |
DisclosureSEC source: 0001093557-17-000009 · edgardoc.xml · derivative · entry 3 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727 Underlying: Common Stock · 3,200 shares Expires 2020-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2017 Filed Jan 13, 2017 00:21 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,200 | $62.86 | $201,152.00 |
DisclosureSEC source: 0001093557-17-000009 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,345 F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 70,084 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 23,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 8,334 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| January 10, 2017 Filed Jan 13, 2017 00:21 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 3,200 | $9.80 | $31,360.00 |
DisclosureSEC source: 0001093557-17-000009 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 19, 2016 Filed Oct 20, 2016 23:55 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 4,997 | $82.31 | $411,303.07 |
DisclosureSEC source: 0001093557-16-000727 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,345 F1 · shares: On December 11, 2015, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 70,084 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 23,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 8,334 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| October 05, 2016 Filed Oct 7, 2016 21:10 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,000 | $82.55 | $412,750.00 |
DisclosureSEC source: 0001093557-16-000717 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,342 F1 · shares: On December 11, 2015, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 70,084 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 23,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 8,334 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 21, 2016 Filed Sep 22, 2016 22:38 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,000 | $92.87 | $464,366.00 |
DisclosureSEC source: 0001093557-16-000709 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,342 F1 · shares: On December 11, 2015, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $92.62 to $93.24. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 70,084 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 23,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 8,334 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 09, 2016 Filed Sep 14, 2016 00:32 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 4,223 | $93.72 | $395,790.54 |
DisclosureSEC source: 0001093557-16-000695 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,342 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 70,084 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 23,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 8,334 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 09, 2016 Filed Sep 14, 2016 00:32 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 4,445 | $93.72 | $416,596.96 |
DisclosureSEC source: 0001093557-16-000695 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,565 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 70,084 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 23,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 8,334 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 07, 2016 Filed Sep 10, 2016 00:49 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,999 | $94.45 Strike: $3.19 | $472,155.55 |
DisclosureSEC source: 0001093557-16-000677 · edgardoc.xml · derivative · entry 3 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,999 shares Expires 2018-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2016 Filed Sep 10, 2016 00:49 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 4,999 | $94.45 | $472,155.55 |
DisclosureSEC source: 0001093557-16-000677 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,010 F1 · shares: On December 11, 2015, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 70,084 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 23,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 8,334 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 07, 2016 Filed Sep 10, 2016 00:49 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 4,999 | $3.19 | $15,946.81 |
DisclosureSEC source: 0001093557-16-000677 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.